Michel Vounatsos, Biogen CEO (via YouTube)
June 7, 2021 11:05 AM EDTUpdated June 8, 12:34 AM
R&D
Pharma
FDA+

FDA OKs ad­u­canum­ab for Alzheimer's, turn­ing con­tro­ver­sial Bio­gen drug in­to a megablock­buster

Jason Mast

Editor

The FDA has ap­proved the Bio­gen drug ad­u­canum­ab for Alzheimer’s, a stun­ning de­ci­sion that caps near­ly two years of con­tro­ver­sy and hands the large biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times